Thought Leadership
At NDA our experts stay abreast with the evolving environment and the new regulatory requirements that it gives rise to. One of the results of these activities is a stream of articles, commentaries and white papers that we publish for the benefit of our clients and followers. It captures the state of the art of our industry today.
We call it Thought Leadership.
Articles and White Papers
Service:
Scientific:
Sort by:
All services
Development Strategy
Medical Devices
Pharmacovigilance
NDA Advisory Board
Strategic Communications
Regulatory
Quality & Compliance
All expertise
Oncology
Vaccine
Immunogenicity
HTA
In-Vitro Diagnostics
Non-Clinical
Cell and Gene Therapy
Biostatistics
Cardiology
ATMP
Rare Disease
Market Access
CMC
Clinical
Paediatric
Acceleration Strategies
Medical Devices
Quality
Patient Safety
08-02-2023
Going Faster – How Project Orbis and ACCESS Consortium Expedite Cross-Jurisdictional Approvals
In this white paper, Ricarda Meinecke provides guidance if you are considering parallel submissions in several jurisdictions for your product.
26-01-2022
Payer Negotiations – Identifying and overcoming the challenges
In this whitepaper, Steffen Thirstrup and Carole Longson highlight the different viewpoints between the regulatory and HTA assessment to guide you on how best to prepare for a positive outcome in both assessments.
08-12-2021
The outlook for gene editing in treating disease
Dr Paula Salmikangas, Dr Björn Carlsson and Dr Steffen Thirstrup address the risks and challenges of gene editing.
29-11-2021
Oral explanation – Your product’s last stand
In this article, we provide insight into oral explanations and what you need to emphasize in a presentation in order to engage with EU regulators.
20-10-2021
Controlled Human Infection Studies
NDA's Dr Paula Salmikangas and Dr Pieter Neels co-wrote and shared their knowledge in this insightful article that was published on the 4th of October in Biologicals.
13-10-2021
A new dawn in Regulation and Access
Scientific Writer, Ingela Loell, provides insight into ILAP and the collaborations providing quicker approval and patient access.